Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy
Quell Therapeutics Ltd (“Quell“), the world leader in developing engineered T-regulatory (Treg) cell therapies for […]
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets […]
XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the […]
AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]
Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease
Fujitsu Limited today announced that it has started joint clinical research with the University of […]
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19
Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating […]
Boston Scientific Eluvia ™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia ™ Drug-Eluting Vascular Stent […]
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for the Treatment of Advanced Solid Tumors
PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and […]
CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19
CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib […]
Pfizer Starts Study of mRNA-based Next Generation Flu Vaccine Program
Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more